Decision Support in Wisconsin

Voximetry provides advanced dosimetry software and clinical services for radiopharmaceutical therapy (RPT), enabling personalized cancer treatment guidance. The company addresses significant variability in patient response to RPT (up to 10-fold differences) through GPU-accelerated dose assessment technology and expert dosimetry services. Voximetry offers three primary service lines: (1) Torch®, a proprietary software platform for analyzing nuclear medicine scans to calculate patient-specific pharmacokinetics and radiation dose estimates to tumors and critical organs; (2) Advanced Dosimetry Services for clinical use, delivered as a managed service to minimize capital expenditure and IT complexity for healthcare providers; and (3) Dosimetry Services for RPT clinical trials, supporting researchers and contract research organizations in meeting trial dosimetry requirements without in-house deployment. The company targets oncology departments, nuclear medicine clinics, academic medical centers, and pharmaceutical companies conducting RPT development. Voximetry operates as a software-as-a-service and laboratory service provider, positioning itself to routinize sophisticated patient-specific dosimetry in clinical practice and clinical research. The organization has partnered with major CROs (e.g., Medpace) and received recognition as a finalist for the 2025 Siemens Healthineers Startup Award.

Merative is a healthcare software and data analytics company offering integrated solutions across clinical imaging, data management, clinical decision support, and health services delivery. The company operates through five primary product lines: Merge (medical imaging and PACS solutions), Micromedex (evidence-based clinical decision support), Truven (healthcare data and analytics), Cúram (health and human services platform for benefits delivery and case management), and Zelta (cloud-based clinical trial data management). Merge provides enterprise imaging platforms, PACS systems, workflow orchestration, and imaging analytics serving 6 of 10 top U.S. health systems and 10 of 20 top U.S. hospitals across 5,500+ sites globally. Micromedex delivers medication-related clinical decision support used by healthcare providers for 40+ years. Truven serves 7 of 10 top U.S. payers and 40% of Fortune 100 employers with healthcare business intelligence and predictive analytics. Cúram supports 970+ social programs across government agencies, processing benefits for 187 million people globally with 200,000+ caseworker users. Zelta supports clinical development with 4,500+ studies across all phases including 500+ Phase III trials. The company serves healthcare systems, payers, employers, government agencies, pharmaceutical sponsors, CROs, and academic medical centers across 80+ countries. Products feature cloud-based deployment, workflow automation, real-world evidence integration, and interoperability with major healthcare IT systems.

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, specializing in cancer detection, diagnosis, and treatment guidance through advanced genomic testing. The company develops and delivers multi-cancer early detection tests, hereditary cancer risk assessment panels, and oncology genomic profiling solutions. Primary product lines include Cologuard (at-home colorectal cancer screening utilizing stool-based DNA testing), Oncotype DX (tissue-based genomic assays for breast, colon, and prostate cancers providing recurrence risk scores and treatment recommendations), and other specialized genomic tests. Exact Sciences operates state-of-the-art CLIA-certified laboratories and conducts rigorous clinical validation studies published in peer-reviewed journals. The company serves patients, healthcare providers, oncologists, and researchers globally, with a focus on enabling informed clinical decision-making through precision medicine. Recently acquired by Abbott, Exact Sciences maintains strong regulatory credentials including FDA clearances for its key diagnostic assays. The company emphasizes collaboration with top medical institutions, advocacy organizations, and policymakers to expand access to genomic cancer testing and improve early detection rates across diverse populations.